Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:05:32.647Z.
Calculation as of: 2026-10-06T18:05:32.647Z.
Quote observation: 2026-10-06T18:04:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c295c1623f78bdf77a886cf07ea1e6d336f06da24b8c95eb76ef4971c7c9c79e
PE RATIO
N/A
Market Cap
$722.00M
PE Ratio
N/A
TTM Avg
991.02
3Y Avg
502.52
5Y Avg
502.52
Market Cap
$712.89M
PE Ratio
17.73
TTM Avg
23.33
3Y Avg
39.10
5Y Avg
32.90
Market Cap
$714.26M
PE Ratio
N/A
TTM Avg
359.25
3Y Avg
359.25
5Y Avg
359.25
Market Cap
$695.70M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Achieve Life Sciences, Inc. (ACHV) | $728.01M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $727.94M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $722.00M | N/A | 991.02 | 502.52 | 502.52 |
| Faeth Therapeutics, Inc. (FTH)vs › | $714.56M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $745.42M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $712.89M | 17.73 | 23.33 | 39.10 | 32.90 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $714.26M | N/A | 359.25 | 359.25 | 359.25 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $698.35M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $695.70M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $764.80M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$7.09
Forward EPS (Est.)
$-1.46
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
